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fate of the dystrophin-associated core proteins in muscular 
dystrophy. Comparative membrane proteomics was used 
to correlate this novel finding to large-scale changes in 
the dystrophic phenotype. A drastic increase in the extra-
cellular stabilizers biglycan and fibronectin was shown by 
both mass spectrometric analysis and immunoblotting. The 
reduced expression of desmoglein in dystrophin-deficient 
skeletal muscles, and simultaneous increase in components 
of the extracellular matrix, suggest that muscular dystrophy 
is associated with plasmalemmal disintegration, loss of cel-
lular linkage and reactive myofibrosis.
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Introduction
The largest gene in the human genome, the 2.4 Mb Dmd 
gene, contains seven promoters and encodes a variety of iso-
forms of the protein dystrophin ranging in molecular mass 
from 71 to 427 kDa (Muntoni et al. 2003). The full-length 
isoform of dystrophin, Dp427, is a membrane cytoskeletal 
protein that exists in a membrane-associated supramolecular 
complex (Murphy and Ohlendieck 2015). The dystrophin 
complex mediates membrane stabilization during excita-
tion–contraction–relaxation cycles and functions as a scaf-
fold for various signalling proteins (Le Rumeur et al. 2010; 
Constantin 2014). In Duchenne muscular dystrophy, primary 
abnormalities in the Dmd gene are the underlying cause for 
the almost complete absence of Dp427 in skeletal muscles 
and the heart, as well as changes in the dystrophin isoform 
expression pattern in the central nervous system (Guiraud 
et al. 2015). Dystrophin-deficient skeletal muscles are char-
acterized by a drastic reduction in dystrophin-associated 
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proteins, such as dystroglycans, sarcoglycans, sarcospan, 
dystrobrevin and syntrophins (Ohlendieck 1996). This 
results in down-stream abnormalities in cellular signalling, 
membrane integrity and energy metabolism (Allen et al. 
2016).
In order to better understand the pathobiochemical com-
plexity of dystrophinopathy and the potential interconnec-
tivity of damage pathways, mass spectrometry-based prot-
eomics has been widely applied to study dystrophic skeletal 
muscles, cardiac abnormalities, the impaired central nervous 
system and serum changes, as outlined in recent reviews 
(Fuller et al. 2016; Hathout et al. 2016). The deficiency in 
dystrophin was shown to be associated with changes in ion 
homeostasis, excitation–contraction coupling, cellular sig-
nalling, the stress response and energy metabolism (Guevel 
et al. 2011; Rayavarapu et al. 2013; Roberts et al. 2015; 
Fröhlich et al. 2016; Lardenois et al. 2016). In addition, 
stabilizing structures of the cytoskeleton and the extracel-
lular matrix are drastically altered (Holland et al. 2013). In 
contrast, only a limited number of studies have focused on 
the proteomics of the core dystrophin complex (Murphy 
and Ohlendieck 2015). The proteomic characterization of 
the dystrophin–glycoprotein complex has employed mass 
spectrometric surveys of separated protein assemblies using 
one-dimensional gel electrophoresis (Lewis and Ohlendieck 
2010), immuno-precipitation (Yoon et al. 2012) and gradient 
centrifugation (Turk et al. 2016).
Building on these proteomic surveys and previous bio-
chemical purification studies of dystrophin (Ervasti et al. 
1990, 1991), we used here a combination of differential 
centrifugation, detergent solubilisation, ion exchange chro-
matography, lectin affinity chromatography, density gradi-
ent ultracentrifugation, gradient one-dimensional gel elec-
trophoresis, on-membrane protein digestion and peptide 
mass spectrometry to characterize the dystrophin complex-
enriched fraction from skeletal muscle by proteomic means. 
The mass spectrometric analysis of normal skeletal mus-
cle resulted in the identification of the cytolinker protein 
desmoglein (Kljuic and Christiano 2003), in conjunction 
with desmoplakin (Boyer et al. 2010), as an interesting new 
candidate protein that possibly exists in close relationship 
to the core sarcolemmal dystrophin–glycoprotein complex. 
Interestingly, comparative immunoblotting revealed a drastic 
decrease of the desmoglein isoform DSG1 in dystrophin-
deficient muscles, which resonates the molecular fate of 
other dystrophin-associated proteins (Ervasti et al. 1990; 
Ohlendieck et al. 1993; Murphy and Ohlendieck 2015).
To relate this novel finding to proteome-wide alterations 
in the dystrophic phenotype, a comparative mass spectro-
metric analysis of the membrane-enriched fraction from 
dystrophic mdx quadriceps muscle was carried out. The 
reduction in desmoglein and deficiency in dystrophin was 
shown to be related to increased levels of the extracellular 
matrix linker proteins biglycan (Amenta et al. 2011) and 
fibronectin, indicating that sarcolemmal disintegration is 
associated with distinct changes in the matrisome (Bowe 
et al. 2000; Holland et al. 2016). Hence, the proteomic and 
biochemical profiling of normal versus dystrophic muscles 
presented in this report indicates new pathophysiological 
roles of desmoglein, biglycan and fibronectin in X-linked 
muscular dystrophy.
Experimental section
Materials
For the gel- and liquid chromatography-based proteomic 
and biochemical profiling of the dystrophin complex and 
membrane fractions from skeletal muscles, analytical grade 
reagents and materials were purchased from GE Healthcare 
(Little Chalfont, Buckinghamshire, UK), Sigma Chemical 
Company (Dorset, UK), Bio-Rad Laboratories (Hemel-
Hempstead, Hertfordshire, UK) and National Diagnostics 
(Atlanta, GA, USA). Proteolytic digestion was carried out 
with sequencing grade modified trypsin and Lys-C enzymes 
from Promega (Madison, WI, USA). Materials for immunob-
lotting included Whatman nitrocellulose transfer membranes 
from Invitrogen (Carlsbad, CA, USA), chemiluminescence 
substrate from Roche Diagnostics (Mannheim, Germany) 
and the reversible membrane stain MemCode from Thermo 
Fisher Scientific (Waltham, MA, USA). Primary antibodies 
were purchased from Abcam, Cambridge, UK (ab124798 to 
desmoglein isoform DSG1, ab2413 to fibronectin, ab58562 
to biglycan, ab52488 to lactate dehydrogenase, ab14739 
to the voltage-dependent anion-selective channel protein 
VDAC-1, and ab16048 to lamin-B1), and Sigma-Aldrich, 
Dorset, UK (L9393 to laminin). Peroxidase-conjugated sec-
ondary antibodies were obtained from Chemicon Interna-
tional (Temecula, CA, USA).
Skeletal muscle preparations
The initial proteomic screening for new potential binding 
partners of dystrophin was carried out with a membrane 
fraction isolated from combined hind limb and back muscle 
tissues of normal adult New Zealand white rabbits, which 
were kept under standard conditions according to Irish legis-
lation on the use of animals in experimental research (Lewis 
and Ohlendieck 2010). Muscle samples from eight rabbits 
were obtained as freshly dissected post-mortem specimens 
from the Bioresource Facility of the National University of 
Ireland and transported as quick-frozen tissue specimens 
to Maynooth University on dry ice in accordance with the 
Department of Agriculture animal by-product register num-
ber 2016/16 (Department of Biology, Maynooth University). 
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For the comparative proteomic profiling of the membrane-
enriched fraction from dystrophic mice, quadriceps femo-
ris muscle specimens from the 100-day-old mdx mouse 
model of Duchenne muscular dystrophy (C57BL/10 ScSn-
Dmdmdx/J) and age-matched wild type C57BL/10 ScSnJ 
controls were obtained from the Animal Facility of the Uni-
versity of Greifswald, Germany (Holland et al. 2015). The 
histological assessment of mdx quadriceps femoris muscle 
morphology was carried out with standardized haematoxy-
lin/eosin staining of transverse cryosections, as previously 
described in detail (Carberry et al. 2013; Zschüntzsch et al. 
2016). The entire mouse population used for experimen-
tal optimisation, comparative proteomics and verification 
analysis consisted of 24 animals (12 wild type versus 12 
mdx mice). Twice eight muscle preparations were used 
for comparative proteomics whereby one set of biological 
repeats consisted of the pooled quadriceps femoris muscle 
from both legs of two mice. For comparative immunob-
lotting, longissimus dorsi muscle, diaphragm and cardiac 
muscle were also used. Mice were kept under standard con-
ditions and all procedures were carried out in accordance 
with German guidelines. The use of animals for scientific 
experiments was approved by the District Veterinary Office 
in Anklam, Germany. Animals were sacrificed by cervi-
cal dislocation after short ether anaesthesia and individual 
muscles dissected and immediately quick-frozen in liquid 
nitrogen and stored at −80 °C prior to usage.
Biochemical isolation of the dystrophin‑enriched 
fraction from skeletal muscle
All procedures were carried out at 4 °C and buffers were 
supplemented with a protease inhibitor cocktail containing 
0.2 mM pefabloc, 0.3 µM E-64, 1.4 µM pepstatin-A, 1 µM 
leupeptin, 0.5 µM soybean trypsin inhibitor, 0.15 µM apro-
tinin and 1 mM EDTA. Crude microsomes were prepared 
from rabbit muscle homogenates by differential centrifu-
gation as previously described in detail (Ohlendieck et al. 
1991). Membrane-associated proteins were solubilized with 
the detergent digitonin and then fractionated by ion exchange 
chromatography and wheat germ agglutinin chromatogra-
phy (Campbell and Kahl 1989). Ultracentrifugation with a 
sucrose density gradient was used to isolate a dystrophin-
enriched fraction that contains the core members of the 
dystrophin-associated glycoprotein complex (Ervasti et al. 
1990).
Gradient gel electrophoresis of dystrophin complex 
and on‑membrane digestion
A Protean IIxi Cell system from BioRad Laboratories 
(Hemel-Hempstead, Hertfordshire, UK) with 16 cm-long 
and 1.5 mm-thick one-dimensional 3–12% gradient gels 
and 100 µg of total protein per lane was used to carry out 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
at a constant setting of 200 V (Staunton and Ohlendieck 
2012). The electrophoretically separated dystrophin fraction 
was then transferred to nitrocellulose for 90 min at 100 V 
with the help of a large Transblot Cell from BioRad Labora-
tories. The reversible protein dyes MemCode or Ponceau-S 
Red were employed to visualize transfer efficiency. Coomas-
sie staining of polyacrylamide gels showed only very few 
remaining faint protein bands following successful transfer. 
For on-membrane digestion, nitrocellulose strips with the 
enriched dystrophin fraction were placed in 15 ml Falcon 
tubes and completely de-stained with 0.9% (w/v) NaCl 
and 50 mM sodium phosphate, pH 7.4. Following repeated 
washing with distilled water, strips were blocked with 0.5% 
polyvinylpyrrolidone for 40 min at 37 °C with gentle agi-
tation and washed again with distilled water before place-
ment in new 15 ml Falcon tubes (Luque-Garcia and Neubert 
2009). Reconstituted sequencing grade trypsin was freshly 
added to digestion buffer consisting of 100 mM ammonium 
bicarbonate/10% acetonitrile (ACN) (1:1, v/v). Nitrocellu-
ose sheets were incubated overnight at 37 °C with agitation 
in this digestion buffer at a 1:20 ratio of trypsin to protein. 
Next morning, extraction buffer [5% formic acid/acetonitrile 
(1:2, v/v)] was added and nitrocellulose strips incubated for 
15 min at 37 °C with agitation (Shevchenko et al. 2006). 
The peptide-containing supernatant was transferred to 1.5 ml 
micro-centrifuge tubes and vacuum centrifugation was used 
to generate a dried peptide fraction, which was re-suspended 
in 0.5% trifluoroacetic acid (TFA)/5% ACN (1:1, v/v). Cen-
trifugation through 22-µm acetate cellulose spin filter tubes 
for 20 min was employed to remove any membrane particles 
and C18 spin columns used to desalt peptides prior to drying 
by vacuum centrifugation and mass spectrometric analysis.
Preparation of membrane‑enriched fraction from wild 
type versus dystrophic mdx quadriceps femoris muscle
For the comparative proteomic profiling of the quadriceps 
femoris muscle from wild type versus dystrophic mdx mice, 
a crude membrane-enriched fraction containing mitochon-
dria, sarcoplasmic reticulum and surface membranes, as well 
as associated components of the extracellular matrix and 
membrane cytoskeleton, was isolated by an optimized dif-
ferential centrifugation method (O’Connell and Ohlendieck 
2009). Briefly, muscle specimens (1 mg wet weight) were 
finely chopped and homogenised in 10 ml of 2 mM HEPES, 
pH 7.4, 220 mM mannitol, 70 mM sucrose (supplemented 
with a protease inhibitor cocktail) and the homogenate cen-
trifuged at 1100g for 5 min to remove cell debris and nuclei. 
The membrane-containing supernatant was retained while 
the pellet was re-suspended in 5 ml of buffer and re-cen-
trifuged. This step was repeated once more with the pellet 
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re-suspended in 2.5 ml of buffer. The supernatants from each 
of these centrifugation steps were pooled and centrifuged at 
7000g for 15 min and the resulting pellet was re-suspended 
in 5 ml of buffer and then centrifuged at 20,000g for 15 min 
to sediment the crude membrane fraction. This step was 
repeated two more times, with the pellet retained at each 
stage. After the final centrifugation step, the pellets were 
pooled together and re-suspended in 2 ml of buffer.
Generation of peptide populations 
from membrane‑enriched fraction
For the generation of distinct peptide populations, mem-
brane fractions from normal versus dystrophic muscles were 
pre-treated with the Ready Prep 2D clean-up kit from Bio-
Rad Laboratories (Hemel-Hempstead, Hertfordshire, UK), 
and the pellets obtained were re-suspended in label-free 
solubilisation buffer consisting of 6 M urea, 2 M thiourea 
and 10 mM Tris, pH 8.0 in LC-MS grade water (Holland 
et al. 2015). Sample volumes were equalised with label-
free solubilisation buffer, reduced with 10 mM DTT for 
30 min at 37 °C and alkylated with 25 mM iodoacetamide 
in 50 mM ammonium bicarbonate for 20 min in the dark at 
room temperature. Samples were then treated with a further 
10 mM DTT for 15 min in the dark at room temperature to 
quench any remaining unreacted iodoacetamide (Murphy 
et al. 2015). Sequential proteolytic digestion was conducted 
with an initial step using Lys-C enzyme at a ratio of 1:100 
(protease:protein) for 4 h at 37 °C, followed by dilution of 
samples with four times the initial sample volume in 50 mM 
ammonium bicarbonate to reduce the urea concentration 
prior to tryptic digestion, and a second step with sequencing-
grade trypsin at a ratio of 1:25 (protease:protein) overnight 
at 37 °C (Dowling et al. 2014). Digestion was halted using 
2% TFA in 20% ACN (3:1 (v/v) dilution). Peptide suspen-
sions were purified with Pierce C18 Spin Columns from 
Thermo Fisher Scientific (Dublin, Ireland), dried through 
vacuum centrifugation and re-suspended in loading buffer 
consisting of 2% ACN and 0.05% TFA in LC-MS grade 
water.
Label‑free liquid chromatography mass spectrometry
An Ultimate 3000 NanoLC system (Dionex Corporation, 
Sunnyvale, CA, USA) coupled to a Q-Exactive mass spec-
trometer (Thermo Fisher Scientific) was used in this study 
for the label-free liquid chromatography mass spectromet-
ric (LC-MS/MS) analysis of the dystrophin-enriched frac-
tion from rabbit skeletal muscle and the crude membrane 
fraction from wild type versus mdx quadriceps femoris 
mouse muscle. Peptide mixtures (5 µl, corresponding to 
1 µg pre-digested protein) were loaded by an autosampler 
onto a C18 trap column (C18 PepMap, 300 µm id × 5 mm, 
5 µm particle size, 100 Å pore size; Thermo Fisher Sci-
entific). The trap column was switched on-line with an 
analytical Biobasic C18 Picofrit column (C18 PepMap, 
75 µm id × 50 cm, 2 µm particle size, 100 Å pore size; 
Dionex).
Peptides obtained from the crude membrane fraction from 
wild type versus mdx quadriceps femoris mouse muscle 
were eluted using the following binary gradients: solvent A 
[2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade 
water] and solvent B [80% (v/v) ACN and 0.1% (v/v) formic 
acid in LC-MS grade water]. Peptides were eluted as fol-
lows: 5% solvent B for 120 min, 45% solvent B for 2.5 min, 
90% solvent B for 9 min and 3% solvent B for 43 min. The 
column flow rate was fixed at 0.3 µl/min.
Peptide populations from the dystrophin-enriched fraction 
from rabbit skeletal muscle were eluted over a 65-min gradi-
ent as follows; 3% solvent B for 5 min, 10% solvent B for 
30 min, 40% solvent B for 5 min, 90% solvent B for 5 min 
and 3% solvent B for 10 min. The column flow rate was set 
to 0.3 µl/min. Data were acquired with Xcalibur software 
(Thermo Fisher Scientific).
The Q-Exactive mass spectrometer was operated in posi-
tive, data-dependent mode and was externally calibrated. 
Survey MS scans were conducted in the 300–1700 m/z 
range with a resolution of 140,000 (m/z 200) and lock mass 
set to 445.12003 (Murphy et al. 2015). Collision-induced 
dissociation (CID) fragmentation was carried out with the 
fifteen most intense ions per scan and at 17,500 resolution. 
A dynamic exclusion window was applied within 30 s. An 
isolation window of 2 m/z and one microscan were used to 
collect suitable tandem mass spectra. Pre-run and post-run 
control HeLa cells were run and the acquired mass spectra 
were analysed by Proteome Discoverer to verify the repro-
ducibility of the LC-MS/MS system.
Proteomic profiling by label‑free liquid 
chromatography mass spectrometry
Qualitative analysis of the dystrophin-enriched fraction from 
rabbit skeletal muscle was performed using Proteome Dis-
coverer 1.4 against Sequest HT (SEQUEST HT algorithm, 
licence Thermo Scientific, registered trademark University 
of Washington, USA) using the UniProtKB database with 
24,202 proteins. Since the rabbit genome is incomplete, mass 
spectrometry raw files were searched against both the Oryc-
tolagus cuniculus database and the Mammalia database (Liu 
et al. 2016). For proper protein identification, the following 
search parameters were used: (1) peptide mass tolerance set 
to 10 ppm, (2) MS/MS mass tolerance set to 0.02 Da, (3) 
up to two missed cleavages, (4) carbamidomethylation set 
as a fixed modification and (5) methionine oxidation set as 
a variable modification. Peptides were subsequently filtered 
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using a minimum XCorr score of 1.5 for 1, 2.0 for 2, 2.25 
for 3 and 2.5 for 4 charge states, with peptide probability set 
to high confidence.
Progenesis QI for Proteomics software (version 3.1; 
Non-Linear Dynamics, a Waters company, Newcastle upon 
Tyne, UK) was used for quantitative analysis of the raw data 
obtained from LC-MS/MS of the crude membrane fraction 
from wild type versus mdx quadriceps femoris mouse mus-
cle. The run containing the most peptide ions was manu-
ally selected as the reference run and all other runs were 
aligned to this, thus allowing for any drift in retention time 
and giving an adjusted retention time for all runs in the 
analysis (Di Luca et al. 2015). A number of filters were 
applied to the MS/MS data files prior to being exported 
as a MASCOT generic file (mgf) to Proteome Discoverer 
2.1 (Thermo Scientific): (1) peptide features with ANOVA 
≤0.05 between experimental groups, (2) mass peaks with 
charge states from +1 to +6 and (3) greater than one iso-
tope per peptide (Holland et al. 2015). Protein identifica-
tion was performed using Proteome Discoverer 2.1 against 
Mascot (version 2.3, Matrix Science, Boston, MA, USA) 
and Sequest HT (SEQUEST HT algorithm, licence Thermo 
Scientific, registered trademark University of Washing-
ton, USA) using the UniProtKB-SwissProt database with 
24,752 proteins. For the comparative proteomic analysis of 
the mdx mouse model, searches were carried out with the 
Mus musculus database. The search parameters used were: 
(1) peptide mass tolerance set to 10 ppm, (2) MS/MS mass 
tolerance set to 0.02 Da, (3) a maximum of two missed 
cleavages allowed, (4) carbamidomethylation set as a fixed 
modification and (5) methionine oxidation set as a vari-
able modification (Murphy et al. 2015). For re-importation 
back into Progenesis LC-MS software as a PepXML file 
only peptides with either ion scores of 40.00 or more (from 
Mascot) and peptides with XCorr score >1.5 (from Sequest 
HT) were allowed. The following criteria were applied to 
assign proteins as confidently identified: (1) an ANOVA 
score between experimental groups of ≤0.05, and (2) pro-
teins with ≥2 peptides matched.
Standard bioinformatics software was used to catalogue 
the clustering of differentially abundant proteins in the 
membrane-enriched fraction from dystrophic mdx muscle 
using the PANTHER database of protein families (http://
pantherdb.org; version 10.0) for the classification of protein 
class (Mi et al. 2013).
Comparative immunoblot analysis
Immunoblotting was employed for both the confirmation of 
membrane enrichment and for the verification of some of the 
key protein hits identified by mass spectrometric analysis. 
Total tissue extracts were prepared from quadriceps femoris, 
longissimus dorsi, diaphragm and cardiac muscle from wild 
type versus mdx mice by a previously optimized method 
(Murphy et al. 2015). Standardized one-dimensional gel 
electrophoresis was performed with 10% polyacrylamide 
gels, followed by wet transfer at 100 V for 70 min at 4 °C 
to Whatman nitrocellulose membranes in a Trans-Blot Cell 
from Bio-Rad Laboratories, as previously described (Mur-
phy et al. 2016). For comparative analyses, silver staining 
of protein gels and routine immunoblotting was carried out 
with 10 and 25 µg of total protein per lane, respectively. 
Membranes were blocked for 1 h at room temperature using 
a milk protein solution [2.5% (w/v) fat-free milk powder in 
10% phosphate buffered saline], and then incubated with 
appropriately diluted primary antibodies overnight at 4 °C 
with gentle agitation. The following day, membranes were 
washed twice in the milk protein solution for 10 min and 
then incubated with peroxidase-conjugated secondary anti-
bodies for 1.5 h at room temperature with gentle agitation. 
Membranes were washed with the milk protein solution and 
then with 10% phosphate-buffered saline (Murphy et al. 
2016). The enhanced chemiluminescence method was used 
to visualise immuno-decorated protein bands (O’Connell 
and Ohlendieck 2009). Densitometric scanning and statisti-
cal analysis of immunoblots was performed using a HP PSC-
2355 scanner and ImageJ software (NIH, Bethesda, MD, 
USA) along with Graph-Pad Prism software (San Diego, 
CA, USA), in which a p value <0.05 was deemed to be sta-
tistically significant.
Results
Mass spectrometric identification of core members 
of the dystrophin‑associated complex from skeletal 
muscle
The dystrophin complex-enriched fraction from rabbit 
skeletal muscle, isolated by an established combination 
of sequential liquid chromatography and sucrose gradi-
ent ultracentrifugation (Ervasti et al. 1990), was clearly 
shown to contain the Dp427 isoform of the membrane 
cytoskeletal protein dystrophin. The bioanalytical approach 
to enrich the dystrophin complex is outlined in Fig. 1A. 
The Ponceau S-stained nitrocellulose replica of the gel 
electrophoretically separated fraction enriched in the rab-
bit muscle dystrophin–glycoprotein complex is shown 
in supplementary Figure S1. The mass spectrometric 
identification of dystrophin Dp427-M with a high Xcorr 
score of 119.94 was based on the information from 28 
peptides with an 8.9% sequence coverage of the 426 kDa 
isoform (Fig. 1b). On-membrane digestion of the dystro-
phin-enriched fraction and mass spectrometry revealed 
the presence of the core dystrophin-associated proteins 
named α/β-dystroglycan, α-sarcoglycan, β-sarcoglycan, 
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γ-sa rcoglycan ,  δ -sa rcoglycan ,  α1-syn t rophin , 
β1-syntrophin, β2-syntrophin and α-dystrobrevin. The 
detailed mass spectrometric identification of these 
established dystrophin-associated proteins is listed in 
Table 1 and demonstrated a successful enrichment of the 
dystrophin complex by density gradient centrifugation.
Dystrophin-associated 
muscle proteins
Dystrophin Dp427-M
DYB
/ / / -SGs
-DG
-DG SSPN
Laminin
Actin
Extracellular
matrix
Cytoskeletal
network
Sarcolemma
Membrane
Skeletal muscle
Microsomes
Homogenization     Subcellular fractionation
Detergent
solubilization
Lectin affinity
chromatography
Ion exchange
chromatography
Density gradient
ultracentrifugation
DYSTROPHIN COMPLEX 
enriched fraction
1D Gradient SDS-PAGE
Gel separated proteins
Electrophoretic transfer
Membrane with gel replica
On-membrane digestion
Representative peptide populations
Mass spectrometric analysis
Proteomic profile of
DYSTROPHIN COMPLEX
Confirmation of 
core dystrophin 
complex
Identification of 
novel dystrophin 
associated 
proteins
Comparative bioanalysis
SYN
Gene 
name
Protein 
name
No. of 
peptides
Coverage
% 
Xcorr 
Score
Molecular 
mass (kDa)
Calculated 
pI
Dmd Dystrophin 
Dp427-M
28 8.9 119.94 426.1 5.96
Mass spectrometric identification of dystrophin Dp427-M
A
B
Fig. 1  Proteomic profiling of the dystrophin complex-enriched frac-
tion from rabbit skeletal muscle. Shown is the bioanalytical workflow 
used to identify dystrophin-associated proteins (a) and the mass spec-
trometric identification of the full-length dystrophin isoform Dp427-
M (b). DG dystroglycan, DYB dystrobrevin, SG sarcoglycan, SSPN 
sarcospan, SYN syntrophin
Table 1  Mass spectrometric identification of established members of the dystrophin-associated protein complex from rabbit skeletal muscle
Gene name Protein name No. unique 
peptides
Coverage (%) Xcorr score
Replicate 1
Xcorr score
Replicate 2
Molecular 
mass (kDa)
Calculated pI
DAG1 α/β-Dystroglycan 2 3.58 6.60 2.75 97.0 8.27
SGCA α-Sarcoglycan 4 11.11 9.11 2.91 42.5 6.19
SGCB β-Sarcoglycan 3 10.06 8.93 3.64 34.7 8.76
SGCG γ-Sarcoglycan 3 12.37 10.20 3.68 32.0 5.25
SGCD δ-Sarcoglycan 4 15.57 14.37 15.50 32.1 8.85
SNTA1 α1-Syntrophin 2 6.97 5.90 4.45 51.8 6.64
SNTB1 β1-Syntrophin 4 11.30 8.60 8.66 58.3 8.31
SNTB2 β2-Syntrophin 2 4.45 3.01 5.37 58.4 8.09
DTNA α-Dystrobrevin 3 8.01 8.92 – 63.3 8.15
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Proteomic identification of co‑purifying and potentially 
novel dystrophin‑associated proteins
Besides the above listed established proteins that were previ-
ously shown to exist in close proximity to dystrophin iso-
form Dp427-M (Murphy and Ohlendieck 2015), interesting 
new candidate proteins that were identified by mass spec-
trometric analysis to co-purify with the dystrophin complex 
are presented in Table 2. These muscle proteins may exist 
in a close relationship to the sarcolemmal dystrophin–gly-
coprotein complex or are alternatively present in the dys-
trophin-enriched fraction as highly abundant contaminants 
from other cellular organelles or subcellular compartments. 
The identified proteins belong to diverse subcellular struc-
tures within skeletal muscles and were identified as the fast 
SERCA1 isoform of the  Ca2+-ATPase (ATP2A1), the anion 
exchange protein (SLC4A1), the cytolinker desmoglein-1 
(DSG1), cytokeratin-3 (KRT3), serum albumin (ALB), the 
cytolinker desmoplakin (DSP) and myosin heavy chain iso-
form IIb (MYH4). Although all of these muscle proteins 
may link directly or at least indirectly to members of the 
sarcolemmal dystrophin complex, the most likely func-
tional interaction partners of the dystrophin complex would 
be presented by the cytoskeletal linker protein desmoglein 
(Kljuic and Christiano 2003) and its binding partner desmo-
plakin (Boyer et al. 2010), as well as the anion exchanger 
and cytokeratin, which can also interact with the cytoskel-
etal network (Ursitti et al. 2004; Stone et al. 2005). In con-
trast, the  Ca2+-ATPase of the highly abundant sarcoplasmic 
reticulum, the myosin heavy chain of the plentiful contractile 
apparatus, and the frequently cross-contaminating albumin 
as the most abundant component of serum are less likely 
to present major novel dystrophin-associated components.
Immunoblot analysis of the cytolinker desmoglein 
in dystrophic mdx muscles
Following the mass spectrometric identification of desmo-
glein and desmoplakin as co-purifying proteins in the dys-
trophin-enriched fraction from skeletal muscle, comparative 
immunoblotting was used to attempt the determination of 
the status of these cytolinkers in normal versus dystrophic 
specimens. However, since immuno-decoration of desmo-
plakin (using two commercially available antibodies) did 
not result in proper labelling of this protein (not shown), the 
subsequent immunoblotting survey focused on desmoglein 
isoform DSG1. Figure 2 shows the comparative analysis of 
quadriceps femoris and longissimus dorsi muscle. While the 
overall protein band patterns in silver-stained gels (Fig. 2a, 
d) and laminin levels (Fig. 2b, e) were shown to be com-
parable between crude extracts from wild type versus mdx 
mice, the concentration of desmoglein was found to be dras-
tically decreased in dystrophin-deficient muscle (Fig. 2c, f). 
The statistical evaluation of immunoblotting revealed that 
the reduced levels of desmoglein are significant (Fig. 2g–j). 
The co-localization of desmoglein and dystrophin in mus-
cle cryosections using immunofluorescence microscopy did 
not result in sufficient immuno-labelling for a reliable cell 
biological assessment (not shown). The lack of proper anti-
body staining is probably due to the low abundance of this 
cytoskeletal linker protein.
Isolation and proteomic characterization 
of a membrane‑enriched fraction from quadriceps 
femoris muscle
In order to correlate the reduced abundance of the newly 
identified cytolinker protein desmoglein to proteome-wide 
changes in the dystrophic phenotype, a comparative mass 
spectrometric analysis of quadriceps femoris preparations 
from normal versus dystrophic mice was initiated. The aim 
was to analyse a crude membrane fraction so that on the 
one hand, sample complexity would be reduced to also 
encompass the analysis of low-abundance proteins, and on 
the other hand, the study of proteins derived from the sur-
face membrane system, mitochondria and the sarcoplasmic 
reticulum could be achieved. The subcellular fractionation 
protocol for the isolation of a very crude membrane frac-
tion employed therefore a relatively slow centrifugation 
step. This approach is based on an established procedure 
Table 2  Mass spectrometric identification of dystrophin co-purifying proteins from rabbit skeletal muscle
Gene name Protein name No. unique 
peptides
Coverage (%) Xcorr score
Replicate 1
Xcorr score
Replicate 2
Molecular 
mass (kDa)
Calculated pI
ATP2A1 Fast SERCA1  Ca2+-ATPase 9 13.76 18.27 22.67 107.9 5.31
SLC4A1 Anion exchange protein 4 6.31 15.13 8.08 102.1 5.24
DSG1 Desmoglein-1 4 5.92 5.69 8.83 113.7 5.06
KRT3 Cytokeratin-3 4 3.82 7.33 9.94 64.3 7.75
ALB Serum albumin 3 5.27 8.05 8.72 69.3 6.18
DSP Desmoplakin 3 1.73 3.52 8.33 278.7 6.95
MYH4 Myosin heavy chain isoform MyHC-IIb 2 1.96 10.63 2.85 222.9 5.81
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especially developed for studying mitochondria (O’Connell 
and Ohlendieck 2009). Previous comparative proteomic 
investigations have employed a 100,000g centrifugation step 
to isolate microsomes prior to mass spectrometric analysis 
and used combined muscles from the entire mouse hind limb 
of the mdx-4cv mouse (Murphy et al. 2015).
In contrast to the previous high-speed centrifugation 
approach to isolate the microsomal fraction, this new 
report focused on a select muscle group, the quadriceps 
femoris muscle from the mdx mouse model of Duchenne 
muscular dystrophy, and used a lower-speed centrifuga-
tion step to study a different subset of proteins that may 
be affected by deficiency in dystrophin. The results of 
the new proteomic survey showed that the concentration 
of a great variety of different protein species is changed 
in X-linked muscular dystrophy, including many mem-
brane-associated proteins, but also components of the 
extracellular matrix and the intracellular cytoskeleton. 
The bioanalytical workflow is depicted in Fig. 3a. The 
successful subcellular fractionation and enrichment of 
membrane proteins was documented by reduced levels 
of the cytosolic marker enzyme lactate dehydrogenase 
and an increased concentration of the membrane protein 
VDAC-1 in the isolated crude membrane fraction from 
skeletal muscle (Fig. 3b). The total number of individual 
proteins in relation to specific organelles and subcellular 
muscle structures as determined by mass spectrometry is 
listed in Fig. 3c.
Comparative proteomic profiling 
of the membrane‑enriched fraction from mdx 
quadriceps femoris muscle
Mass spectrometry-based subproteomics revealed a large 
number of protein species with a changed abundance in 
dystrophin-deficient mdx quadriceps femoris muscle. A 
M. quadriceps femoris
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Fig. 2  Immunoblot analysis of the cytolinker protein desmoglein 
in dystrophin-deficient skeletal muscle extracts. Shown are silver-
stained gels (A, D) and corresponding immunoblots labelled with 
antibodies to the basal lamina component laminin (LAM; B, E), and 
the cytolinker desmoglein isoform 1 (DSG1; C, F). Lanes 1 and 2 
represent 100-day-old wild type (wt) versus age-matched mdx quadri-
ceps femoris (A–C) and longissimus dorsi (D–F) muscle, respectively. 
Molecular mass standards are marked on the left of panels. The com-
parative blotting between crude extracts from wild type versus mdx 
mice was statistically evaluated using an unpaired Student’s t test 
(Mean values ± SEM; n = 4; **p < 0.01; G–J)
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histological assessment of wild type muscle morphology 
versus the dystrophic phenotype is shown in Fig. 4, demon-
strating a high fraction of central nucleation and a greater 
variability of fibre diameters in the mdx quadriceps femo-
ris muscle. Detailed overviews of haematoxylin and eosin 
stained skeletal muscles from the dystrophic mdx mouse 
model of Duchenne muscular dystrophy have previously 
been published (Carberry et al. 2013), including quadri-
ceps femoris muscle (Zschüntzsch et al. 2016). Tables 3 
and 4 list major muscle proteins with a significantly reduced 
versus increased density in dystrophic muscle, respectively. 
Supplementary Table S1 consists of an additional list of 
increased proteins with a lower fold-change as presented 
in Table 4. A summary of these findings is given in Fig. 5 
showing graphically the bioinformatics PANTHER analysis 
of changed protein classes. Importantly, the most drastically 
reduced protein in membranes from dystrophic muscle tis-
sue was identified as the Dp427-M isoform of dystrophin, 
which confirms the mutant status of the mdx mouse model 
of Duchenne muscular dystrophy used in this investigation 
Fig. 3  Isolation of membrane-
enriched fraction from wild 
type versus dystrophic skeletal 
muscle. Shown is the work-
flow of the isolation of the 
membrane-enriched fraction 
from normal and dystrophic 
mdx quadriceps femoris muscle 
and subsequent comparative 
proteomic profiling (a). In b is 
shown a silver-stained gel and 
corresponding immunoblots 
labelled with antibodies to the 
membrane marker VDAC-1 
and the cytosolic marker lactate 
dehydrogenase. Lanes 1 to 4 
represent total extracts and 
enriched membranes isolated 
from wild type (wt) and mdx 
quadriceps femoris muscle, 
respectively. Molecular mass 
standards are marked on the left 
of panels. The total number of 
mass spectrometrically identi-
fied muscle proteins in relation 
to different organelles and 
subcellular structures is sum-
marized in c. Protein data are 
based on the annotation feature 
in the Proteome Discoverer 2.1 
software program
A B
C
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(Table 3). Since the significant increase in fibronectin and 
biglycan indicated remodelling of the extracellular matrix 
(Table 4), immunoblotting was used to independently verify 
these proteomic results.
Immunoblot analysis of fibronectin and biglycan 
in dystrophic mdx muscles
Following the proteomic identification of desmoglein 
as being potentially a novel dystrophin-associated pro-
tein with a reduction in muscular dystrophy, the status of 
the extracellular matrix proteins fibronectin and biglycan 
was evaluated by immunoblotting. Comparative immuno-
labelling of fibronectin revealed an elevated density of this 
extracellular protein in crude extracts from mdx quadriceps 
femoris (Fig. 6c) and longissimus dorsi (Fig. 6f) muscles. 
In contrast, general protein expression levels and laminin 
abundance were found to be comparable between wild type 
and dystrophic muscle preparations (Fig. 6a, b, d, e). The 
elevated concentration of fibronectin was shown to be sta-
tistically significant (Fig. 6g–j).
The dystrophin complex-associated protein biglycan 
was also found to be elevated in mdx muscle extracts. 
Immunoblotting had to be carried out under non-reducing 
Fig. 4  Histological analysis of 
wild type (wt) versus dystrophic 
mdx skeletal muscle. Shown are 
transverse sections of quadri-
ceps femoris muscles from 100-
day old wild type (a) and mdx 
(b) mice. Cryosections were 
stained with hematoxylin and 
eosin. Bar equals 50 μm
Table 3  Mass spectrometric identification of proteins with a reduced abundance in the dystrophic mdx quadriceps femoris muscle
Accession number Gene name Protein name Unique 
peptides
Confidence score Anova (p) Fold change
P11531 Dmd Dystrophin Dp427-M 3 167.07 8.23E−05 −56.75
P15949 Klk1b9 Kallikrein 1-related peptidase b9 3 196.89 0.0083 −29.71
P23953 Ces1c Carboxylesterase 1C 4 262.6 0.0062 −18.92
P12710 Fabp1 Fatty acid-binding protein, liver 2 116.96 0.0370 −8.53
Q8R429 Atp2a1 SERCA1 Calcium-ATPase 2 103.52 0.0240 −6.46
Q00623 Apoa1 Apolipoprotein A-I 4 179.01 0.0382 −5.27
P21107 Tpm3 Tropomyosin alpha-3 chain 5 304.33 0.0003 −4.32
P09542 Myl3 Myosin light chain 3 4 240.66 0.0010 −3.46
Q91Z83 Myh7 Myosin-7 17 1199.37 0.0080 −3.43
Q8CI51 Pdlim5 PDZ and LIM domain protein 5 2 146.73 0.0455 −2.34
Q9JJW5 Myoz2 Myozenin-2 3 207.04 0.0018 −2.16
Q5XKE0 Mybpc2 Myosin-binding protein C, fast-type 3 166.12 0.0076 −2.07
P10649 Gstm1 Glutathione S-transferase Mu 1 3 161.17 0.0073 −1.92
Q3V1D3 Ampd1 AMP deaminase 1 2 157.93 0.0310 −1.85
P58771 Tpm1 Tropomyosin alpha-1 chain 3 264.03 0.0371 −1.79
Q62234 Myom1 Myomesin-1 2 119.56 0.0379 −1.62
Q9WUB3 Pygm Glycogen phosphorylase, muscle form 6 437.86 0.0196 −1.48
Q5SX39 Myh4 Myosin-4 8 667.87 0.0484 −1.47
P47934 Crat Carnitine O-acetyltransferase 2 192.68 0.0217 −1.47
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conditions to accommodate the binding properties of 
the specific antibody used to detect biglycan. Optimiza-
tion studies were carried out to achieve proper immuno-
labelling of biglycan under reducing versus non-reducing 
conditions (not shown). In contrast to comparable band 
patterning in protein gels (Fig. 7a, d, g) and unchanged 
laminin levels (Fig. 7b, e, h), immuno-decoration of bigly-
can revealed drastic increases in dystrophin-deficient mdx 
quadriceps femoris, longissimus dorsi and diaphragm 
muscle (Fig. 7c, f, i). Interestingly, biglycan expression 
does not appear to be affected in mdx heart (Fig. 7l). Equal 
loading of cardiac muscle samples was demonstrated with 
immunoblotting of lamin isoform B1 (Fig. 7j, k). Figure 8 
shows graphically the statistical analysis of the immunob-
lot analysis of biglycan.
Discussion
X-linked muscular dystrophy is a multi-system disorder with 
chronic skeletal muscle degeneration that is accompanied by 
sterile inflammation, fatty tissue replacement and reactive 
myofibrosis (Holland et al. 2016), as well as late-onset car-
diomyopathy and cognitive impairments in a select number 
of patients (Guiraud et al. 2015). The pathophysiological 
complexity of dystrophinopathies therefore warrants detailed 
large-scale investigations into dystrophin and the molecu-
lar pathogenesis triggered by the primary deficiency in this 
essential membrane cytoskeletal component. However, the 
large size of the supramolecular assembly of full-length 
dystrophin and its tightly associated membrane proteins, as 
well as its relatively low abundance in crude tissue extracts, 
Table 4  Mass spectrometric identification of proteins with an increased abundance in the dystrophic mdx quadriceps femoris muscle
Supplementary Table S1 lists additional proteins with an increased abundance change below fourfold
Accession Gene name Protein name Unique 
peptides
Confidence score Anova (p) Fold change
P13542 Myh8 Myosin-8 7 445.03 1.29E−06 486.30
Q9WTR5 Cdh13 Cadherin-13 2 175.15 0.0204 89.06
P31725 S100a9 Protein S100-A9 2 127.94 0.0142 83.63
Q60854 Serpinb6 Serpin B6 2 130.39 0.0001 77.55
P11276 Fn1 Fibronectin 3 163.85 0.0018 20.87
P09541 Myl4 Myosin light chain 4 2 163.42 4.48E−06 17.59
P13541 Myh3 Myosin-3 10 604.8 0.0047 14.13
Q922F4 Tubb6 Tubulin beta-6 chain 4 234.39 0.0006 9.08
Q3THE2 Myl12b Myosin regulatory light chain 12B 2 109.11 0.0114 9.03
P62270 Rps18 40S ribosomal protein S18 3 203.22 0.0004 8.71
Q8VDD5 Myh9 Myosin-9 2 146.64 0.0050 8.69
P18760 Cfl1 Cofilin-1 3 250.83 1.34E−05 7.01
P62242 Rps8 40S ribosomal protein S8 2 144.03 0.0218 6.60
P26041 Msn Moesin 2 110.08 0.0004 6.30
P09103 P4hb Protein disulfide-isomerase 3 162.63 0.0009 5.98
P10107 Anxa1 Annexin A1 3 216.16 1.47E−05 5.90
P51881 Slc25a5 ADP/ATP translocase 2 2 132.1 0.0030 5.83
Q9WVA4 Tagln2 Transgelin-2 3 169.11 0.0001 5.47
P27773 Pdia3 Protein disulfide-isomerase A3 8 465.71 6.35E−06 5.33
P24369 Ppib Peptidyl-prolyl cis–trans isomerase 2 169.3 0.0014 5.08
P16045 Lgals1 Galectin-1 3 294.54 0.0003 4.68
Q8CI43 Myl6b Myosin light chain 6B 2 151.26 3.16E-05 4.65
P62281 Rps11 40S ribosomal protein S11 2 116.64 0.0056 4.54
P62264 Rps14 40S ribosomal protein S14 3 221.92 0.0014 4.43
Q9CZX8 Rps19 40S ribosomal protein S19 3 139.44 0.0001 4.29
P28653 Bgn Biglycan 4 288.89 0.0048 4.17
P13020 Gsn Gelsolin 6 433.48 0.0001 4.15
P60867 Rps20 40S ribosomal protein S20 3 208.74 0.0036 4.13
P19324 Serpinh1 Serpin H1 5 283.56 2.97E−05 4.12
P0C0S6 H2afz Histone H2A.Z 2 98.13 0.0013 4.09
P80314 Cct2 T-complex protein 1 subunit beta 2 142.27 0.0070 4.05
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make its systematic proteomic characterization technically 
challenging (Murphy and Ohlendieck 2015). To address 
this bioanalytical issue, the proteomic analysis described 
in this report employed a comprehensive approach consist-
ing of both the mass spectrometric identification of novel 
dystrophin-associated proteins and a comparative analy-
sis of complex protein changes in the membrane-enriched 
fraction from dystrophic mdx quadriceps muscle. Thus, the 
main underlying objectives of this investigation were the 
proteomic establishment of dystrophin-associated proteins 
and the systematic analysis of major secondary changes in 
dystrophin-deficient muscle.
The mass spectrometric analysis of the dystrophin 
complex using interaction proteomics suggests that the 
cytolinker proteins desmoglein and desmoplakin (Boyer 
et al. 2010) might interact directly or indirectly with core 
members of the dystrophin complex. Desmoglein isoform 
DSG1 and desmoplakin are sarcolemma-associated proteins 
and are well-established components of heart desmosomes 
(Sonnenberg and Liem 2007) with a primary involvement 
in cardiomyopathy (Brooke et al. 2012). However, both pro-
teins appear to exist at a much lower concentration also in 
voluntary muscles as compared to the heart. The functional 
significance of cytolinker proteins is not well characterized 
in skeletal muscles (Kljuic and Christiano 2003), making 
it difficult to precisely categorize desmoglein/desmoplakin 
function. In general, the main contractile, stabilizing and 
cytoskeletal proteins belonging to the sarcomeric units and 
its associated subcellular structures can be categorised into 
(1) the core contractile elements of the actomyosin appa-
ratus, including myosin heavy chains, myosin light chains, 
actins, troponins and tropomyosins, (2) the supportive skel-
eton of the sarcomere with its high-molecular-mass com-
ponents titin, nebulin, myosin binding proteins, α-actinin 
and myomesin, (3) the associated cytoskeletal network 
consisting of tubulin, desmin and cortical actin, and (4) the 
membrane cytoskeleton-associated proteins spectrin, talin, 
dystrophin, ankyrin and vinculin (Holland and Ohlendieck 
2013).
Desmoglein and desmoplakin probably fall into an addi-
tional category of proteins involved in cytolinking and cel-
lular adhesion, such as those protein complexes present in 
cardiac desmosomes (Sonnenberg and Liem 2007). Since 
desmoglein isoform DSG1 levels are greatly reduced in 
muscular dystrophy, which is a pathobiochemical hallmark 
of all dystrophin-associated proteins in muscular dystro-
phy (Ohlendieck et al. 1993), they might represent novel 
dystrophin-associated proteins of low abundance that are 
possibly involved in cell–cell adhesion processes in skeletal 
muscle tissue. Thus, besides the core dystrophin–glycopro-
tein complex consisting of sarcoglycans, dystroglycans, dys-
trobrevins, syntrophins, sarcospan, laminin and actin (Erv-
asti et al. 1990), as confirmed by detailed proteomic studies 
(Yoon et al. 2012; Turk et al. 2016), dystrophin also links 
indirectly to the wider extracellular and intracellular matrix 
(Bowe et al. 2000; Stone et al. 2005; Rezniczek et al. 2007). 
The loss of dystrophin appears to affect the entire structural 
linkage between the extracellular collagen/proteoglycan 
network and the internal cytoskeleton resulting in impaired 
lateral transmission of contractile force in dystrophic skeletal 
muscles (Ramaswamy et al. 2011).
Interestingly, the comparative proteomic analysis of mdx 
skeletal muscles and independent verification by immu-
noblotting established significantly increased levels of the 
extracellular matrix proteins fibronectin and biglycan (Bowe 
et al. 2000; Mercado et al. 2006). This agrees with the idea 
of severe myofibrosis playing a key role in the molecular 
pathogenesis of muscular dystrophy (Holland et al. 2016). 
Among the tested subtypes of skeletal muscle, the biglycan 
increase was most pronounced in the diaphragm muscle. 
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Fig. 5  Summary of altered protein classes in the membrane-enriched 
fraction from mdx quadriceps femoris muscle. The bioinformatics 
software programme PANTHER (Mi et al. 2013) was used to summa-
rize the clustering of protein classes based on the mass spectromet-
ric analysis of the membrane-enriched fraction from mdx versus wild 
type muscle (Tables 3, 4, as well as supplementary Table S1)
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This result agrees with the previous findings that the dia-
phragm is preferentially affected in the mdx mouse and the 
only muscle showing severe fibre wasting and myofibro-
sis at early stages (Stedman et al. 1991; Steinberger et al. 
2015). Since elevated biglycan levels were previously also 
established as damage markers (Nastase et al. 2012), these 
proteomic alterations may be useful to establish new bio-
marker candidates of dystrophinopathy-related myofibrosis 
(Ohlendieck and Swandulla 2017).
In addition to fibronectin and biglycan, other key extra-
cellular matrix components also showed an increased abun-
dance in dystrophic muscle tissue, including the leucine-
rich repeat proteins prolargin and asporin, as well as the 
collagen binding protein serpin H1. Besides dystrophin, a 
drastic reduction was established for the extracellular pro-
tease named kallikrein 1-related peptidase b9, which medi-
ates major endopeptidase activity. It is difficult to interpret 
this pathophysiological change, but the functions of the kal-
likrein-related peptidases are believed to intersect with the 
class of matrix metalloproteinases (Yoon et al. 2013). This 
functional protease axes appears to be affected by pathologi-
cal dysregulation and might therefore influence the activ-
ity patterns of matrix metalloproteinases, which are major 
control factors in extracellular matrix remodelling. Thus, 
reduced levels of the kallikrein-related peptidase might play 
a role in fibrosis.
Besides reactive myofibrosis, changes in a considerable 
number of protein families may be related to muscle regener-
ation, remodelling of the contractile apparatus and cytoskel-
eton, as well as an increased cellular stress response and 
immune cell infiltration (Shin et al. 2013; Spencer and Tid-
ball 2001). Considerable alterations in the density of nucleic 
acid binding proteins, hydrolases and many other types of 
enzymes were observed, suggesting a significant impact of 
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Fig. 6  Immunoblot analysis of fibronectin in dystrophin-deficient 
skeletal muscle extracts. Shown are silver-stained gels (A, D) and cor-
responding immunoblots labelled with antibodies to the basal lamina 
component laminin (LAM; B, E), and the extracellular matrix protein 
fibronectin (FN; C, F). Lanes 1 and 2 represent 100-day-old wild type 
(wt) versus age-matched mdx quadriceps femoris (A–C) and longis-
simus dorsi (D–F) muscle, respectively. Molecular mass standards 
are marked on the left of panels. The comparative blotting between 
crude extracts from wild type versus mdx mice was statistically evalu-
ated using an unpaired Student’s t test (Mean values ± SEM; n = 4; 
*p < 0.05; G–J)
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dystrophin deficiency on many essential cellular processes 
(Allen et al. 2016). Decreases and increases were especially 
observed in the class of cytoskeletal proteins, which agrees 
with the primary abnormality in a membrane cytoskeletal 
protein and the compensatory up-regulation of the micro-
tubular protein tubulin and the intermediate filament pro-
tein vimentin, as well as moesin, which mediates connec-
tions between the plasmalemma and cytoskeletal structures 
(Lambert et al. 2016). An interesting protein with a reduced 
concentration is the FABP1 isoform of fatty acid-binding 
protein. Its concentration change agrees with the idea of 
altered metabolic rates in muscular dystrophy. Overall, the 
list of increased proteins suggested extensive changes in the 
actomyosin apparatus, adhesion receptor networks, the ribo-
somal complex and the cellular stress response system that 
might be related to molecular and cellular adaptations in the 
mdx quadriceps femoris muscle. The occurrence of muscular 
dystrophy-related cellular transformation would agree with 
changes in the shape-change sensitive actin-crosslinking 
protein transgelin that was previously shown to alter its con-
centration during fibre type shifting in transforming skeletal 
muscles (Donoghue et al. 2007).
The observed decreases in slow myosin heavy chain 
(myosin-7), myosin heavy chain MyHC-2b (myosin-4) and 
slow myosin light chain MLC3, in conjunction with altera-
tions in the levels of tropomyosins Tpm1 and Tpm3, the 
M-line components myomesin-1, myomesin-3 and obscurin, 
the fast myosin-binding protein MyBP-C, the actin-mod-
ulating protein gelsolin and the Z-line protein myozenin, 
suggest complex changes in sarcomeric organization (Lin 
et al. 2017) and possibly a certain degree of fibre type shift-
ing in muscular dystrophy (Dowling et al. 2016). This would 
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Fig. 7  Immunoblot analysis of biglycan in dystrophin-deficient 
muscle extracts. Shown are silver-stained gels (A, D, G, J) and cor-
responding immunoblots labelled with antibodies to the basal lamina 
component laminin (LAM; B, E, H), the nuclear protein lamin B1 
(LB1; K) and the extracellular matrix protein biglycan (BGY; C, F, 
I, L). Lanes 1 and 2 represent 100-day-old wild type (wt) versus age-
matched mdx muscle samples, respectively. Immunoblotting was car-
ried out with crude extracts isolated from quadriceps femoris muscle 
(A–C), longissimus dorsi muscle (D–F), diaphragm muscle (G–I) and 
the heart (J–L). Molecular mass standards are marked on the left of 
panels 
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agree with the identified alterations in fibre type-specific 
isoforms of major  Ca2+-regulatory proteins, such as the 
decreased levels of the fast SERCA1 isoform of the sar-
coplasmic reticulum  Ca2+-ATPase versus the concomitant 
increase in the slow isoform of the  Ca2+-binding protein 
calsequestrin of the terminal cisternae region (Culligan et al. 
2002). Drastic increases in myosin-3 and myosin-8, which 
represent embryonic and perinatal isoforms of myosin heavy 
chains, and the fetal isoform of myosin light chain 4, may 
be involved in cycles of muscle degeneration and regenera-
tion (Holland et al. 2015). The increased concentration of 
cellular myosin-9, cofilin-1 and nexilin, which are linked to 
cytokinesis and cytoskeleton reorganization, may promote 
cell spreading, cell migration and changes in cell shape dur-
ing fibre regeneration. Higher levels of the  Ca2+-dependent 
cell adhesion protein cadherin-13 possibly acts as a modi-
fying factor during muscle cell growth, and galectin-1 as 
a regulator of muscle cell proliferation and fibre differen-
tiation. The proteomic identification of increased obscurin 
would also agree with enhanced myofibrillogenesis, since 
this crucial M-line protein plays a central organisational role 
in myofibrillar assembly during sarcomere changes (Gautel 
and Djinović-Carugo 2016).
The proteomic analysis of the mdx quadriceps femo-
ris muscle indicated an enhanced cellular stress response, 
which is in agreement with previous proteomic studies of the 
severely dystrophic and fibrotic mdx diaphragm (Doran et al. 
2006). Drastic increases in the key enzymes protein-disulfide 
isomerase and peptidyl-prolyl-cis-trans isomerase, as well as 
a large variety of heat shock proteins including Hsp90-beta, 
HspA9, HspB1, mitochondrial HspD1, glucose-regulated 
HspA5, HspB6, T-complex protein 1 and aB-crystallin, 
demonstrated that molecular chaperones are highly abun-
dant in dystrophin-deficient muscle tissues. These diverse 
stress proteins are involved in the promotion of accelerated 
peptide folding to support muscle proteins in resuming their 
functional fold, the initiation of refolding mechanisms to sta-
bilize compromised protein structures, the aversion of high 
levels of detrimental protein aggregation and accompany-
ing proteotoxic side effects, as well as the swift removal 
of irreversibly misfolded protein species (Brinkmeier and 
Ohlendieck 2014).
In addition to the stress response and cycles of cel-
lular degeneration and regeneration, the immune system 
also plays a critical role in dystrophinopathies, whereby 
a key feature of degenerating muscle fibres is immune 
Fig. 8  Significant changes 
of the extracellular matrix 
protein biglycan in dystrophic 
mdx skeletal muscles. Shown 
is the graphical presentation 
of the statistical evaluation of 
the immunoblots depicted in 
Fig. 7. The comparative blotting 
between crude extracts from 
100-day-old wild type (wt) ver-
sus age-matched mdx mice was 
statistically evaluated using an 
unpaired Student’s t test (Mean 
values ± SEM; n = 4; *p < 0.05, 
**p < 0.01). Shown is the analy-
sis of laminin, lamin B1 and 
biglycan using crude extracts 
from quadriceps femoris muscle 
(A, B), longissimus dorsi muscle 
(C, D), diaphragm muscle (E, 
F) and the heart (G, H)
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cell infiltration (Villalta et al. 2015). It is not fully under-
stood whether sterile inflammation occurs as a separate 
pathological process that is independent of muscle fibre 
degeneration or is triggered by a relatively non-specific 
and mostly reactive invasion of immune cells in damaged 
contractile fibres (Rosenberg et al. 2015; Villalta et al. 
2014). Biochemical and proteomic studies of the inflam-
matory pathology of dystrophic muscles have established 
that progressive muscle wasting is reflected by an altered 
rate of protein release into the circulatory system and 
other significant plasma fluctuations (Hathout et al. 2016). 
Serum analysis using both conventional gel electrophore-
sis in combination with densitometric scanning (John and 
Purdom 1989) and label-free LC-MS/MS (Murphy et al. 
2017) revealed a significantly increased concentration of 
the inflammation-inducible plasma marker haptoglobin in 
muscular dystrophy. Since this acute phase response pro-
tein is a reliable marker of inflammation that is usually 
associated with tissue damage (Wang et al. 2001), dystro-
phinopathies appear to be closely linked to sterile inflam-
mation. Proteomic findings presented in this report agree 
with this pathophysiological scenario.
The  Ca2+–Zn2+-binding protein S100-A9, which has a 
key regulatory role in the immune response and inflamma-
tory processes (Goyette and Geczy 2011), was shown to 
be drastically increased in dystrophic muscle. The S100a9 
gene is regulated by various inflammatory mediators, which 
alter its expression level within a particular inflammatory 
milieu. The S100A9 protein is constitutively expressed in 
neutrophils and can induce neutrophil chemotaxis. Elevated 
levels of annexin isoform A1 that exhibits anti-inflammatory 
activity suggest that the innate immune response plays an 
important part in the molecular pathogenesis of X-linked 
muscular dystrophy. Various members of the annexin family 
have previously been identified to exhibit changed expres-
sion levels in muscular dystrophy (Holland et al. 2015). The 
apparent compensatory up-regulation of annexin 1 is an 
interesting finding, since this annexin isoform acts as a criti-
cal regulator of the overall inflammatory process. Annexin 
1 was shown to counteract inflammatory events and thereby 
promotes the restoration of cellular homeostasis (Sugimoto 
et al. 2016), which might also occur in dystrophin-deficient 
muscle tissues.
Importantly, the concomitant decrease in the desmo-
glein/desmoplakin-complex and increase in the biglycan/
fibronectin-network illustrates the complexity of pathobio-
chemical changes and adaptations in dystrophin-deficient 
skeletal muscle tissues (Bowe et al. 2000; Amenta et al. 
2011). It is remarkable that the proteomic screening pro-
cedure described in this report resulted in a successful 
identification of these new biomarker candidates of muscle 
damage, since a large number of technical challenges are 
especially associated with the biochemical and proteomic 
analysis of muscle tissues. Skeletal muscles are (1) het-
erogeneous in their cellular composition in relation to dif-
ferent subtypes of contractile fibres, innervating neurons, 
glia cells, satellite cells and capillaries, (2) highly plastic 
in their adaptive potential, (3) and surrounded by several 
layers of connective tissue, which complicates extraction 
procedures. A serious biochemical problem for efficient 
protein separation is the large number of high-molecular-
mass proteins, such as titin, nebulin, obscurin, dysferlin, 
dystrophin and the ryanodine receptor. Since approximately 
half of the muscle protein species belong to the contractile 
apparatus, the potential cross-contamination with myosins, 
actins, tropomyosins and troponins presents also an inves-
tigative difficulty. Thus, pathoproteomic surveys of tissue 
specimens from muscular dystrophy are not straightforward 
bioanalytical endeavours.
Although a considerable number of proteomic studies 
have identified many dystrophinopathy-related secondary 
alterations in proteins involved in metabolism, signalling 
events and structural integrity, most large-scale comparative 
studies have failed to detect dystrophin (Holland et al. 2013). 
This serious analytical drawback was overcome in this study 
by using sophisticated subcellular fractionation procedures. 
In this proteomic study, the drastic reduction in dystrophin 
could be directly compared with secondary abnormalities 
in a variety of enzymes, structural proteins and signalling 
components.
Conclusions
Interaction proteomics using an analytical co-purification 
approach identified the cytolinkers desmoglein and desmo-
plakin as potentially new dystrophin-associated proteins. 
In analogy to the reduction of all core dystrophin-asso-
ciated proteins in muscular dystrophy, immunoblotting 
established significantly lower desmoglein isoform DSG1 
levels in dystrophin-deficient muscle tissue. The compara-
tive proteomic profiling of a muscle membrane-enriched 
fraction from the mdx mouse model of Duchenne muscu-
lar dystrophy could furthermore establish increased lev-
els of fibronectin and biglycan of the extracellular matrix. 
Since the proteoglycan biglycan exists in a close rela-
tionship to dystrophin, this finding agrees with a central 
role of an altered matrisome and reactive myofibrosis in 
dystrophinopathy.
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